Oncotelic Therapeutics, Inc. (OTCQB: OTLC) announced that its subsidiary Sapu Nano will present new data on everolimus toxicology at the Society of Toxicology 2026 Annual Meeting and ToxExpo in San Diego. The presentation will focus on findings regarding tissue concentration–driven effects and organ-specific outcomes, moving beyond traditional plasma pharmacokinetics to better understand toxicity profiles.
The research underscores the importance of tissue-level drug distribution in determining the safety and efficacy of therapeutics. By analyzing how everolimus accumulates in various tissues, the study aims to inform the development of improved delivery strategies, including intravenous and nanoparticle-based formulations. These approaches could enhance the therapeutic index of everolimus, a drug commonly used in oncology, by reducing off-target toxicity while maintaining or improving its anticancer activity.
Everolimus is an mTOR inhibitor approved for several cancers, but its use is often limited by side effects related to systemic exposure. Sapu Nano’s nanoparticle platform seeks to address these limitations by targeting drug delivery more precisely to tumor sites. The data to be presented at SOT 2026 will provide preclinical evidence supporting this strategy, potentially paving the way for safer and more effective treatments.
The announcement is significant for Oncotelic as it highlights the progress of its subsidiary, Sapu Nano, in advancing nanomedicine technologies. The company is focused on developing next-generation drug delivery systems to unlock new clinical potential for established therapeutics. Oncotelic itself is a biotechnology company with a pipeline targeting rare pediatric cancers and other diseases, leveraging artificial intelligence through its acquisition of PointR Data Inc.
Oncotelic holds rare pediatric disease designations for Diffuse Intrinsic Pontine Glioma (DIPG) through OT-101, melanoma through CA4P, and acute myeloid leukemia through OXi 4503. The company also acquired AL-101 for intranasal delivery of apomorphine, targeting Parkinson's disease and other conditions. The everolimus data presented at SOT 2026 could support broader applications of Sapu Nano’s platform beyond oncology.
The SOT Annual Meeting is a key venue for toxicology research, and the presentation positions Oncotelic and Sapu Nano at the forefront of understanding drug distribution and toxicity. For more information, the full press release is available at https://ibn.fm/kZzE3. Updates on Oncotelic can be found in their newsroom at https://ibn.fm/OTLC.
